February 20, 2024 6:58am

After a roller-coaster week, does it continue?

News: Harvard Apparatus GT (HRGN) desperately finances with $500 K bridge loan (2/1) from Chairman & CEO He; it’s very telling rejection by U.S. investors and capital markets and antipathy of past Chinese investors which have NOT stepped-up (again) while officer sees WHAT hope in own money? At the least the “public shell” has value.  Interesting the covenants included certain definitions of “Act of Bankruptcy”? <8-K>

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading! Join me … in the NO spin zone!

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

There is no breadline for share pricing and fact-based intelligence!

I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

 

Tuesday: The pre-open Dow futures are DOWN -0.34% or (-130 points), the S&P futures are DOWN -0.33% or (-21 points) as the Nasdaq futures are DOWN -0.52% or (-91 points)

U.S. futures are falling on Tuesday after Monday’s market holiday,

European equities were lower,

Asia-Pacific markets closed mixed

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Friday, the Dow closed DOWN -145.13 points or -0.37%, the S&P closed DOWN -24.16 points -0.48% while the Nasdaq closed DOWN -130.52 points or -0.82%

Last week’s whiplash action snapped a five-week winning streak.

For the week, the S&P 500 was down -0.42%, the Dow -0.11%, while the Nasdaq is poised to slide -1.34%. 

Economic Data Docket: economic data on nonmanufacturing at 10 a.m.

 

From the title: Harvard Apparatus GT (HRGN) – 8-K:

https://finance.yahoo.com/sec-filing/HRGN/0001493152-24-005102_1563665

 

Friday’s night RegMed Investors (RMi) Closing Bell: “the cell and gene therapy closed barely positive after a bumpy session. A 5-week winning streak ended the week negative.” …  https://www.regmedinvestors.com/articles/13335

 

Q1/24: February – 1 market holiday, 8 positive and 4 negative closes

  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

I am passing on forecasting the daily indications – the aftermarket is just too “cloudy” and mixed signals.

 

The BOTTOM LINE: The cell and gene therapy sector equities on Friday with 3 positive and 2 negative closes last week.

The remainder of the month’s trading sessions will be critical as the RegMed sector continues earnings’ in LPS (loss-per-share) season, estimates and consensus which set market reaction and will report “runways” and those whose cash positions render their future questionable.

 

I reiterate, “Don't chase the cell and gene therapy sector, especially with the Nasdaq extended.”

Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

 

Earnings’ Whispers:

Fate Therapeutics (FATE) is expected to post quarterly loss of $0.57 per share in its upcoming report, which represents a year-over-year change of +1.7%. Revenues are expected to be $0.85 million, down 98.1% from the year-ago quarter. <ZACKS>

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.